{"id":"NCT03927703","sponsor":"Novan, Inc.","briefTitle":"A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC","officialTitle":"A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-13","primaryCompletion":"2019-11-11","completion":"2020-02-03","firstPosted":"2019-04-25","resultsPosted":"2023-01-20","lastUpdate":"2023-03-23"},"enrollment":355,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Molluscum Contagiosum"],"interventions":[{"type":"DRUG","name":"SB206 12%","otherNames":["berdazimer sodium"]},{"type":"DRUG","name":"Placebo","otherNames":["Vehicle Gel"]}],"arms":[{"label":"SB206 12%","type":"EXPERIMENTAL"},{"label":"Placebo Comparator","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects â‰¥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.","primaryOutcome":{"measure":"Complete Clearance of All Treatable MC at Week 12","timeFrame":"12 Weeks","effectByArm":[{"arm":"SB206","deltaMin":71,"sd":null},{"arm":"Placebo","deltaMin":24,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["34909721"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":237},"commonTop":["Application Site Pain","Application site erythema","Application site scar"]}}